These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16336751)

  • 1. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
    Kuo T; Fisher GA
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S62-70. PubMed ID: 16336751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
    Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
    Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
    Snyder LC; Astsaturov I; Weiner LM
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
    Kim GP; Grothey A
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S89-97. PubMed ID: 16336754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
    Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E
    Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
    Ng K; Zhu AX
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):8-20. PubMed ID: 18006328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
    Gandara DR; Davies AM; Gautschi O; Mack PC; Lau DH; Lara PN; Hirsch FR
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S61-7. PubMed ID: 17382026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.
    Amador ML; Hidalgo M
    Clin Colorectal Cancer; 2004 May; 4(1):51-62. PubMed ID: 15207021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.